The association between exposure to statin drugs and favourable treatment outcomes for various types of infections has been established.
Dr Park and colleagues from Korea analzyed the clinical characteristics and treatment outcomes of Clostridium difficile infection among hospitalized patients taking statin drugs.
The team reviewed the medical records for consecutive in-patients with Clostridium difficile infection confirmed by positive toxin assay C. difficile culture, or the presence of pseudomembrane on endoscopy.
Treatment success was defined as the resolution of diarrhoea within 6 days of therapy.
|The overall response to metronidazole was 92%|
|Alimentary Pharmacology & Therapeutics|
The primary end points were assessed by average symptom recovery time and treatment response.
Among 949 patients, the overall response to metronidazole was 92%.
The doctors noted that the baseline characteristics showed some differences between statin users and statin non-users with respect to mean disease severity score.
The team observed that successful treatment response was significantly associated with the absence of exposure to proton pump inhibitors and with exposure to statins.
Contrary to the treatment response, univariate and multivariate analyses failed to show that exposure to PPIs or statins affected symptom recovery times.
The research team found that 60-day Clostridium difficile infection recurrence rates for those patients with statin exposure were significantly lower compared with those patients without statin exposure.
Dr Park's team concludes, "Prior statin exposure in patients with C. difficile infection is associated with a successful response to treatment."